Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Superdrol is the brand name for methasterone (also known as methyldrostanolone), a synthetic and orally active anabolic-androgenic steroid (AAS). It is a 17α-methylated derivative of drostanolone, designed to be orally bioavailable while maintaining high anabolic potency. The compound acts as an agonist of the androgen receptor, primarily in skeletal muscle tissue, to promote significant increases in muscle mass and strength. Originally introduced in 2005 by Designer Supplements as a "designer supplement," it was never approved for medical use by the FDA and was eventually banned and classified as a Schedule III controlled substance in 2012 due to its potential for abuse and hepatotoxicity. While the brand name is currently used for other products, the original Superdrol refers specifically to the methasterone compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methasterone.